TMDX Stock — TransMedics Group, Inc.

TransMedics Group, Inc. (TMDX)

TMDX is a low-cost Stock. Fund total return is 295.5% over the past 7.3 years, 101.4 points ahead of SPY at 194.1%.

TransMedics Group is a medical technology company that develops and commercializes the Organ Care System (OCS), a portable technology that preserves and monitors donor organs outside the human body to improve transplant outcomes for patients with end-stage organ failure. The company offers OCS platforms for lung, heart, and liver preservation, along with organ management and logistics services including transportation and coordination. The company does not currently distribute to shareholders.

TMDX performance versus SPY

Data as of August 28, 2026.

Fund total return is 295.5% over the past 7.3 years, 101.4 points ahead of SPY at 194.1%. Its deepest 1-year drawdown was 58.8%.

TMDX key facts

Data as of August 28, 2026.

Asset type

Stock

Asset class

Equity

Inception date

05/02/2019

Distribution frequency

None

Last close

$88.43

Market cap

$3,197,741,824

Average volume

629879.0

Beta

1.88

Payout ratio

0.0

P/E ratio

24.2684

Forward P/E

65.3595

EPS

$3.80

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) is the latest regular payout annualized by the fund's stated frequency, divided by the last close. Issuers often publish this as “Distribution Rate” on the fact sheet. Trailing-12-month yield is the sum of distributions paid in the last 12 months, split-adjusted, divided by the last close. It lags a recent raise or cut. We show a 30-day SEC yield when the fund publishes one. Schwab and other issuers may report a TTM distribution yield or SEC yield on a different date — all can be valid; they are not interchangeable. Fund total return uses split-adjusted close with distributions reinvested from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is what the fund did, not your personal gain/loss. Figures below use Dividend Vision data as of August 28, 2026.

Distribution rate methodology · Distribution Safety Score methodology · SEC yield

Sources and review

Data as of August 28, 2026.

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

TMDX risks and drawbacks

The deepest 1-year drawdown on record here is 58.8%.

Who may consider TMDX — and who may not

TMDX may suit someone looking for low-cost broad dividend exposure. It is a weaker fit for investors who need monthly cash flow (TMDX does not currently distribute); investors hunting double-digit covered-call yields. This is educational context, not a recommendation to buy or sell.

Frequently asked questions